



Dear Chair and Members of the Committee:

On behalf of Americans for Prosperity-Nevada and our activists across the state, we urge you to respectfully oppose AB 555, which proposes a price cap on insulin for certain health insurers in the state of Nevada. Americans for Prosperity supports policy that removes barriers to health care access, improves affordability or allows for patients to have choice and control of their care through free market principles.

At first glance, the intent behind AB 555, to make insulin more affordable for Nevadans, is commendable. Diabetes affects thousands of families, and addressing access to life-saving medication is critical. However, this bill attempts to solve a deeply rooted problem through a policy approach that is both short-sighted and counterproductive: government-imposed price caps.

Price controls, no matter how well-intentioned, are a top-down mandate that distorts the free market. AB 555 would set a fixed out-of-pocket cost of no more than \$35 for a 30-day supply of insulin for certain private insurance plans, compelling insurers to treat insulin differently than other medical treatments or drugs. In doing so, the bill not only interferes with the natural price mechanisms of the market but also risks creating a cascade of unintended consequences—reduced competition, supply disruptions, and increased premiums elsewhere in the system to offset capped costs.

The legislation also grants sweeping authority to the Commissioner of Insurance to penalize insurers, revoke certifications, and apply these mandates to out-of-state coverage in certain cases. Such expansive regulatory power may chill innovation and reduce insurer participation in the Nevada market, ultimately harming consumers.

Instead of price caps, lawmakers should focus on solutions that foster transparency, competition, and consumer choice. Policies that encourage generic alternatives, reform the role of pharmacy benefit managers (PBMs), and eliminate regulatory barriers to new market entrants will better serve patients in the long term. Empowering patients and promoting competition will drive prices down sustainably—without the unintended harm that price controls often inflict.

In conclusion, while the affordability of insulin is a pressing concern, AB 555 is the wrong approach. Americans for Prosperity – Nevada for these reasons, urges lawmakers to reject this bill and instead pursue market-driven solutions that respect consumer choice and preserve innovation.

Thank you for your time and consideration.

Sincerely,

RONNIE NAJARRO

STATE DIRECTOR

RNAJARRO@AFPHQ.ORG